6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	NN	following	following	follow	N	O
is	VBZ	is	is	is	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
more	JJR	more	more	more	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
sections	NNS	sections	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
labeling	NN	labeling	labeling	label	N	O
:	:	:	:	:	N	O

Seizure	NN	seizure	seizure	seizur	Y	B-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)]	NN	)]	)]	)]	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
asthenia	JJ	asthenia	asthenia	asthenia	Y	B-AdverseReaction
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	NN	appetite	appetite	appetit	N	I-AdverseReaction
,	,	,	,	,	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
,	,	,	,	,	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
hot	JJ	hot	hot	hot	N	B-AdverseReaction
flush	NN	flush	flush	flush	N	I-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
weight	NN	weight	weight	weight	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
vertigo	NN	vertigo	vertigo	vertigo	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
Astellas	NNP	astellas	astellas	astella	N	O
Pharma	NNP	pharma	pharma	pharma	N	O
US	NNP	us	u	us	N	O
,	,	,	,	,	N	O
Inc	NNP	inc	inc	inc	N	O
.	.	.	.	.	N	O

at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
727	CD	727	727	727	N	O
-	:	-	-	-	N	O
7003	CD	7003	7003	7003	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trial	NNP	trial	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
a	DT	a	a	a	N	O
drug	NN	drug	drug	drug	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
of	IN	of	of	of	N	O
another	DT	another	another	anoth	N	O
drug	NN	drug	drug	drug	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

Two	CD	two	two	two	N	O
randomized	JJ	randomized	randomized	random	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
enrolled	VBD	enrolled	enrolled	enrol	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
metastatic	JJ	metastatic	metastatic	metastat	N	O
prostate	NN	prostate	prostate	prostat	N	O
cancer	NN	cancer	cancer	cancer	Y	O
that	WDT	that	that	that	N	O
has	VBZ	has	ha	ha	N	O
progressed	VBN	progressed	progressed	progress	N	O
on	IN	on	on	on	N	O
androgen	NN	androgen	androgen	androgen	N	O
deprivation	NN	deprivation	deprivation	depriv	N	O
therapy	NN	therapy	therapy	therapi	N	O
(	(	(	(	(	N	O
GnRH	NNP	gnrh	gnrh	gnrh	N	O
therapy	NN	therapy	therapy	therapi	N	O
or	CC	or	or	or	N	O
bilateral	JJ	bilateral	bilateral	bilater	N	O
orchiectomy	NN	orchiectomy	orchiectomy	orchiectomi	Y	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
a	DT	a	a	a	N	O
disease	NN	disease	disease	diseas	N	O
setting	VBG	setting	setting	set	N	O
that	WDT	that	that	that	N	O
is	VBZ	is	is	is	N	O
also	RB	also	also	also	N	O
defined	VBN	defined	defined	defin	N	O
as	IN	as	a	as	N	O
metastatic	JJ	metastatic	metastatic	metastat	N	O
CRPC	NNP	crpc	crpc	crpc	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
both	DT	both	both	both	N	O
studies	NNS	studies	study	studi	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
received	VBD	received	received	receiv	N	O
XTANDI	JJ	xtandi	xtandi	xtandi	N	O
160	CD	160	160	160	N	O
mg	NN	mg	mg	mg	N	O
orally	RB	orally	orally	oral	N	O
once	RB	once	once	onc	N	O
daily	JJ	daily	daily	daili	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
active	JJ	active	active	activ	N	O
treatment	NN	treatment	treatment	treatment	N	O
arm	NN	arm	arm	arm	N	O
or	CC	or	or	or	N	O
placebo	NN	placebo	placebo	placebo	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
control	NN	control	control	control	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
continued	VBD	continued	continued	continu	N	O
androgen	JJ	androgen	androgen	androgen	N	O
deprivation	NN	deprivation	deprivation	depriv	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
allowed	VBN	allowed	allowed	allow	N	O
,	,	,	,	,	N	O
but	CC	but	but	but	N	O
not	RB	not	not	not	N	O
required	VBN	required	required	requir	N	O
,	,	,	,	,	N	O
to	TO	to	to	to	N	O
take	VB	take	take	take	N	O
glucocorticoids	NNS	glucocorticoids	glucocorticoid	glucocorticoid	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
more	JJR	more	more	more	N	O
commonly	RB	commonly	commonly	commonli	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
over	IN	over	over	over	N	O
placebo	NN	placebo	placebo	placebo	N	O
)	)	)	)	)	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
randomized	VBD	randomized	randomized	random	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
were	VBD	were	were	were	N	O
asthenia	JJ	asthenia	asthenia	asthenia	Y	B-AdverseReaction
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
appetite	NN	appetite	appetite	appetit	N	I-AdverseReaction
,	,	,	,	,	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
,	,	,	,	,	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
hot	JJ	hot	hot	hot	N	B-AdverseReaction
flush	NN	flush	flush	flush	N	I-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
edema	NN	edema	edema	edema	Y	I-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
musculoskeletal	JJ	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
weight	NN	weight	weight	weight	Y	B-AdverseReaction
decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
,	,	,	,	,	N	O
headache	NN	headache	headache	headach	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
vertigo	NN	vertigo	vertigo	vertigo	Y	B-AdverseReaction
.	.	.	.	.	N	O

Study	NN	study	study	studi	N	O
1	CD	1	1	1	N	O
:	:	:	:	:	N	O
Metastatic	JJ	metastatic	metastatic	metastat	N	O
Castration	NNP	castration	castration	castrat	N	O
-	:	-	-	-	N	O
Resistant	JJ	resistant	resistant	resist	N	O
Prostate	NNP	prostate	prostate	prostat	N	O
Cancer	NNP	cancer	cancer	cancer	Y	O
Following	NNP	following	following	follow	N	O
Chemotherapy	NNP	chemotherapy	chemotherapy	chemotherapi	Y	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
enrolled	VBD	enrolled	enrolled	enrol	N	O
1199	CD	1199	1199	1199	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
metastatic	JJ	metastatic	metastatic	metastat	N	O
CRPC	NNP	crpc	crpc	crpc	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
previously	RB	previously	previously	previous	N	O
received	VBN	received	received	receiv	N	O
docetaxel	NN	docetaxel	docetaxel	docetaxel	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
was	VBD	was	wa	wa	N	O
8.3	CD	8.3	8.3	8.3	N	O
months	NNS	months	month	month	N	O
with	IN	with	with	with	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
and	CC	and	and	and	N	O
3.0	CD	3.0	3.0	3.0	N	O
months	NNS	months	month	month	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

During	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
48%	CD	48%	48%	48%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
arm	NN	arm	arm	arm	N	O
and	CC	and	and	and	N	O
46%	CD	46%	46%	46%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
arm	NN	arm	arm	arm	N	O
received	VBD	received	received	receiv	N	O
glucocorticoids	NNS	glucocorticoids	glucocorticoid	glucocorticoid	N	O
.	.	.	.	.	N	O

Grade	VB	grade	grade	grade	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
higher	JJR	higher	higher	higher	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
among	IN	among	among	among	N	O
47%	CD	47%	47%	47%	N	O
of	IN	of	of	of	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
53%	CD	53%	53%	53%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Discontinuations	NNS	discontinuations	discontinuation	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
for	IN	for	for	for	N	O
16%	CD	16%	16%	16%	N	O
of	IN	of	of	of	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
18%	CD	18%	18%	18%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
was	VBD	was	wa	wa	N	O
seizure	NN	seizure	seizure	seizur	Y	B-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
none	NN	none	none	none	N	O
(	(	(	(	(	N	O
0%	CD	0%	0%	0%	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
shows	NNS	shows	show	show	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
2%	CD	2%	2%	2%	N	O
higher	JJR	higher	higher	higher	N	O
frequency	NN	frequency	frequency	frequenc	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
arm	NN	arm	arm	arm	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
1	CD	1	1	1	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O

XTANDI	NNP	xtandi	xtandi	xtandi	N	O
N	NNP	n	n	n	N	O
800	CD	800	800	800	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
N	NNP	n	n	n	N	O
399	CD	399	399	399	N	O

Grade	$	grade	grade	grade	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
a	DT	a	a	a	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

General	NNP	general	general	gener	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Asthenic	NNP	asthenic	asthenic	asthen	N	B-AdverseReaction
Conditionsb	NNP	conditionsb	conditionsb	conditionsb	N	I-AdverseReaction
50.6	CD	50.6	50.6	50.6	N	O
9.0	CD	9.0	9.0	9.0	N	O
44.4	CD	44.4	44.4	44.4	N	O
9.3	CD	9.3	9.3	9.3	N	O

Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
Edema	NNP	edema	edema	edema	Y	I-AdverseReaction
15.4	CD	15.4	15.4	15.4	N	O
1.0	CD	1.0	1.0	1.0	N	O
13.3	CD	13.3	13.3	13.3	N	O
0.8	CD	0.8	0.8	0.8	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
And	CC	and	and	and	N	O
Connective	NNP	connective	connective	connect	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Back	RB	back	back	back	N	B-AdverseReaction
Pain	NNP	pain	pain	pain	Y	I-AdverseReaction
26.4	CD	26.4	26.4	26.4	N	O
5.3	CD	5.3	5.3	5.3	N	O
24.3	CD	24.3	24.3	24.3	N	O
4.0	CD	4.0	4.0	4.0	N	O

Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
20.5	CD	20.5	20.5	20.5	N	O
2.5	CD	2.5	2.5	2.5	N	O
17.3	CD	17.3	17.3	17.3	N	O
1.8	CD	1.8	1.8	1.8	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
Pain	NNP	pain	pain	pain	Y	I-AdverseReaction
15.0	CD	15.0	15.0	15.0	N	O
1.3	CD	1.3	1.3	1.3	N	O
11.5	CD	11.5	11.5	11.5	N	O
0.3	CD	0.3	0.3	0.3	N	O

Muscular	JJ	muscular	muscular	muscular	N	B-AdverseReaction
Weakness	NNP	weakness	weakness	weak	Y	I-AdverseReaction
9.8	CD	9.8	9.8	9.8	N	O
1.5	CD	1.5	1.5	1.5	N	O
6.8	CD	6.8	6.8	6.8	N	O
1.8	CD	1.8	1.8	1.8	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	B-AdverseReaction
Stiffness	NNP	stiffness	stiffness	stiff	Y	I-AdverseReaction
2.6	CD	2.6	2.6	2.6	N	O
0.3	CD	0.3	0.3	0.3	N	O
0.3	CD	0.3	0.3	0.3	N	O
0.0	CD	0.0	0.0	0.0	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
21.8	CD	21.8	21.8	21.8	N	O
1.1	CD	1.1	1.1	1.1	N	O
17.5	CD	17.5	17.5	17.5	N	O
0.3	CD	0.3	0.3	0.3	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Hot	NNP	hot	hot	hot	N	B-AdverseReaction
Flush	NNP	flush	flush	flush	N	I-AdverseReaction
20.3	CD	20.3	20.3	20.3	N	O
0.0	CD	0.0	0.0	0.0	N	O
10.3	CD	10.3	10.3	10.3	N	O
0.0	CD	0.0	0.0	0.0	N	O

Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
6.4	CD	6.4	6.4	6.4	N	O
2.1	CD	2.1	2.1	2.1	N	O
2.8	CD	2.8	2.8	2.8	N	O
1.3	CD	1.3	1.3	1.3	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
System	NNP	system	system	system	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
12.1	CD	12.1	12.1	12.1	N	O
0.9	CD	0.9	0.9	0.9	N	O
5.5	CD	5.5	5.5	5.5	N	O
0.0	CD	0.0	0.0	0.0	N	O

Dizzinessc	NNP	dizzinessc	dizzinessc	dizzinessc	N	B-AdverseReaction
9.5	CD	9.5	9.5	9.5	N	O
0.5	CD	0.5	0.5	0.5	N	O
7.5	CD	7.5	7.5	7.5	N	O
0.5	CD	0.5	0.5	0.5	N	O

Spinal	NNP	spinal	spinal	spinal	N	B-AdverseReaction
Cord	NNP	cord	cord	cord	N	I-AdverseReaction
Compression	NNP	compression	compression	compress	N	I-AdverseReaction
and	CC	and	and	and	N	O
Cauda	NNP	cauda	cauda	cauda	N	B-AdverseReaction
Equina	NNP	equina	equina	equina	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
7.4	CD	7.4	7.4	7.4	N	O
6.6	CD	6.6	6.6	6.6	N	O
4.5	CD	4.5	4.5	4.5	N	O
3.8	CD	3.8	3.8	3.8	N	O

Paresthesia	NNP	paresthesia	paresthesia	paresthesia	Y	B-AdverseReaction
6.6	CD	6.6	6.6	6.6	N	O
0.0	CD	0.0	0.0	0.0	N	O
4.5	CD	4.5	4.5	4.5	N	O
0.0	CD	0.0	0.0	0.0	N	O

Mental	JJ	mental	mental	mental	N	B-AdverseReaction
Impairment	NNP	impairment	impairment	impair	N	I-AdverseReaction
Disordersd	NNP	disordersd	disordersd	disordersd	N	I-AdverseReaction
4.3	CD	4.3	4.3	4.3	N	O
0.3	CD	0.3	0.3	0.3	N	O
1.8	CD	1.8	1.8	1.8	N	O
0.0	CD	0.0	0.0	0.0	N	O

Hypoesthesia	$	hypoesthesia	hypoesthesia	hypoesthesia	Y	B-AdverseReaction
4.0	CD	4.0	4.0	4.0	N	O
0.3	CD	0.3	0.3	0.3	N	O
1.8	CD	1.8	1.8	1.8	N	O
0.0	CD	0.0	0.0	0.0	N	O

Infections	NNS	infections	infection	infect	N	O
And	CC	and	and	and	N	O
Infestations	NNS	infestations	infestation	infest	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
Respiratory	NNP	respiratory	respiratory	respiratori	N	I-AdverseReaction
Tract	NNP	tract	tract	tract	N	I-AdverseReaction
Infectione	NNP	infectione	infectione	infection	N	I-AdverseReaction
10.9	CD	10.9	10.9	10.9	N	O
0.0	CD	0.0	0.0	0.0	N	O
6.5	CD	6.5	6.5	6.5	N	O
0.3	CD	0.3	0.3	0.3	N	O

Lower	JJR	lower	lower	lower	N	B-AdverseReaction
Respiratory	NNP	respiratory	respiratory	respiratori	N	I-AdverseReaction
Tract	NNP	tract	tract	tract	N	I-AdverseReaction
And	CC	and	and	and	N	O
Lung	NNP	lung	lung	lung	N	B-AdverseReaction
Infectionf	NNP	infectionf	infectionf	infectionf	N	I-AdverseReaction
8.5	CD	8.5	8.5	8.5	N	O
2.4	CD	2.4	2.4	2.4	N	O
4.8	CD	4.8	4.8	4.8	N	O
1.3	CD	1.3	1.3	1.3	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
8.8	CD	8.8	8.8	8.8	N	O
0.0	CD	0.0	0.0	0.0	N	O
6.0	CD	6.0	6.0	6.0	N	O
0.5	CD	0.5	0.5	0.5	N	O

Anxiety	NN	anxiety	anxiety	anxieti	Y	B-AdverseReaction
6.5	CD	6.5	6.5	6.5	N	O
0.3	CD	0.3	0.3	0.3	N	O
4.0	CD	4.0	4.0	4.0	N	O
0.0	CD	0.0	0.0	0.0	N	O

Renal	NNP	renal	renal	renal	N	O
And	CC	and	and	and	N	O
Urinary	NNP	urinary	urinary	urinari	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Hematuria	NNP	hematuria	hematuria	hematuria	Y	B-AdverseReaction
6.9	CD	6.9	6.9	6.9	N	O
1.8	CD	1.8	1.8	1.8	N	O
4.5	CD	4.5	4.5	4.5	N	O
1.0	CD	1.0	1.0	1.0	N	O

Pollakiuria	NNP	pollakiuria	pollakiuria	pollakiuria	Y	B-AdverseReaction
4.8	CD	4.8	4.8	4.8	N	O
0.0	CD	0.0	0.0	0.0	N	O
2.5	CD	2.5	2.5	2.5	N	O
0.0	CD	0.0	0.0	0.0	N	O

Injury	NNP	injury	injury	injuri	Y	O
,	,	,	,	,	N	O
Poisoning	NNP	poisoning	poisoning	poison	Y	O
And	CC	and	and	and	N	O
Procedural	NNP	procedural	procedural	procedur	N	O
Complications	NNP	complications	complication	complic	N	O

Fall	NN	fall	fall	fall	Y	B-AdverseReaction
4.6	CD	4.6	4.6	4.6	N	O
0.3	CD	0.3	0.3	0.3	N	O
1.3	CD	1.3	1.3	1.3	N	O
0.0	CD	0.0	0.0	0.0	N	O

Non	NNP	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
pathologic	NN	pathologic	pathologic	patholog	N	I-AdverseReaction
Fractures	VBZ	fractures	fracture	fractur	N	I-AdverseReaction
4.0	CD	4.0	4.0	4.0	N	O
1.4	CD	1.4	1.4	1.4	N	O
0.8	CD	0.8	0.8	0.8	N	O
0.3	CD	0.3	0.3	0.3	N	O

Skin	NNP	skin	skin	skin	N	O
And	CC	and	and	and	N	O
Subcutaneous	NNP	subcutaneous	subcutaneous	subcutan	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Pruritus	NNP	pruritus	pruritus	pruritu	Y	B-AdverseReaction
3.8	CD	3.8	3.8	3.8	N	O
0.0	CD	0.0	0.0	0.0	N	O
1.3	CD	1.3	1.3	1.3	N	O
0.0	CD	0.0	0.0	0.0	N	O

Dry	NNP	dry	dry	dri	N	B-AdverseReaction
Skin	NNP	skin	skin	skin	N	I-AdverseReaction
3.5	CD	3.5	3.5	3.5	N	O
0.0	CD	0.0	0.0	0.0	N	O
1.3	CD	1.3	1.3	1.3	N	O
0.0	CD	0.0	0.0	0.0	N	O

Respiratory	NN	respiratory	respiratory	respiratori	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Epistaxis	NNP	epistaxis	epistaxis	epistaxi	Y	B-AdverseReaction
3.3	CD	3.3	3.3	3.3	N	O
0.1	CD	0.1	0.1	0.1	N	O
1.3	CD	1.3	1.3	1.3	N	O
0.3	CD	0.3	0.3	0.3	N	O

a	DT	a	a	a	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
v4b	NN	v4b	v4b	v4b	N	O
Includes	NNP	includes	includes	includ	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
.	.	.	.	.	N	O
c	VB	c	c	c	N	O
Includes	NNP	includes	includes	includ	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
vertigo	NN	vertigo	vertigo	vertigo	Y	B-AdverseReaction
.	.	.	.	.	N	O
d	NN	d	d	d	N	O
Includes	NNP	includes	includes	includ	N	O
amnesia	NN	amnesia	amnesia	amnesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
memory	NN	memory	memory	memori	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
,	,	,	,	,	N	O
cognitive	JJ	cognitive	cognitive	cognit	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
disturbance	NN	disturbance	disturbance	disturb	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
attention	NN	attention	attention	attent	N	I-AdverseReaction
.	.	.	.	.	N	O
e	NN	e	e	e	N	O
Includes	NNP	includes	includes	includ	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
,	,	,	,	,	N	O
rhinitis	NN	rhinitis	rhinitis	rhiniti	Y	B-AdverseReaction
,	,	,	,	,	N	O
pharyngitis	NN	pharyngitis	pharyngitis	pharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
laryngitis	NN	laryngitis	laryngitis	laryng	Y	B-AdverseReaction
.	.	.	.	.	N	O
f	NN	f	f	f	N	O
Includes	NNP	includes	includes	includ	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
lower	JJR	lower	lower	lower	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	JJ	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
lung	NN	lung	lung	lung	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
.	.	.	.	.	N	O

Study	NN	study	study	studi	N	O
2	CD	2	2	2	N	O
:	:	:	:	:	N	O
Chemotherapy	NNP	chemotherapy	chemotherapy	chemotherapi	Y	O
-	:	-	-	-	N	O
naive	JJ	naive	naive	naiv	N	O
Metastatic	NNP	metastatic	metastatic	metastat	N	O
Castration	NNP	castration	castration	castrat	N	O
-	:	-	-	-	N	O
Resistant	JJ	resistant	resistant	resist	N	O
Prostate	NNP	prostate	prostate	prostat	N	O
Cancer	NNP	cancer	cancer	cancer	Y	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
enrolled	VBD	enrolled	enrolled	enrol	N	O
1717	CD	1717	1717	1717	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
metastatic	JJ	metastatic	metastatic	metastat	N	O
CRPC	NNP	crpc	crpc	crpc	N	O
who	WP	who	who	who	N	O
had	VBD	had	had	had	N	O
not	RB	not	not	not	N	O
received	VBN	received	received	receiv	N	O
prior	RB	prior	prior	prior	N	O
cytotoxic	JJ	cytotoxic	cytotoxic	cytotox	N	O
chemotherapy	NN	chemotherapy	chemotherapy	chemotherapi	Y	O
,	,	,	,	,	N	O
of	IN	of	of	of	N	O
whom	WP	whom	whom	whom	N	O
1715	CD	1715	1715	1715	N	O
received	VBD	received	received	receiv	N	O
at	IN	at	at	at	N	O
least	JJS	least	least	least	N	O
one	CD	one	one	one	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
study	JJ	study	study	studi	N	O
drug	NN	drug	drug	drug	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
median	JJ	median	median	median	N	O
duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
treatment	NN	treatment	treatment	treatment	N	O
was	VBD	was	wa	wa	N	O
17.5	CD	17.5	17.5	17.5	N	O
months	NNS	months	month	month	N	O
with	IN	with	with	with	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
and	CC	and	and	and	N	O
4.6	CD	4.6	4.6	4.6	N	O
months	NNS	months	month	month	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Grade	$	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
44%	CD	44%	44%	44%	N	O
of	IN	of	of	of	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
37%	CD	37%	37%	37%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Discontinuations	NNS	discontinuations	discontinuation	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
for	IN	for	for	for	N	O
6%	CD	6%	6%	6%	N	O
of	IN	of	of	of	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
6%	CD	6%	6%	6%	N	O
of	IN	of	of	of	N	O
placebo	NN	placebo	placebo	placebo	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
was	VBD	was	wa	wa	N	O
fatigue	JJ	fatigue	fatigue	fatigu	Y	B-AdverseReaction
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
on	IN	on	on	on	N	O
each	DT	each	each	each	N	O
treatment	NN	treatment	treatment	treatment	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
includes	VBZ	includes	includes	includ	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
that	WDT	that	that	that	N	O
occurred	VBD	occurred	occurred	occur	N	O
at	IN	at	at	at	N	O
a	DT	a	a	a	N	O
2%	CD	2%	2%	2%	N	O
higher	JJR	higher	higher	higher	N	O
frequency	NN	frequency	frequency	frequenc	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
arm	NN	arm	arm	arm	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
placebo	NN	placebo	placebo	placebo	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

Table	NN	table	table	tabl	N	O

2	CD	2	2	2	N	O
.	.	.	.	.	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O

XTANDI	NNP	xtandi	xtandi	xtandi	N	O
N	NNP	n	n	n	N	O
871	CD	871	871	871	N	O
Placebo	NNP	placebo	placebo	placebo	N	O
N	NNP	n	n	n	N	O
844	CD	844	844	844	N	O

Grade	$	grade	grade	grade	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
a	DT	a	a	a	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

General	NNP	general	general	gener	N	O

Disorders	NNS	disorders	disorder	disord	N	O

Asthenic	NNP	asthenic	asthenic	asthen	N	B-AdverseReaction
Conditionsb	NNP	conditionsb	conditionsb	conditionsb	N	I-AdverseReaction
46.9	CD	46.9	46.9	46.9	N	O
3.4	CD	3.4	3.4	3.4	N	O
33.0	CD	33.0	33.0	33.0	N	O
2.8	CD	2.8	2.8	2.8	N	O

Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
Edema	NNP	edema	edema	edema	Y	I-AdverseReaction
11.5	CD	11.5	11.5	11.5	N	O
0.2	CD	0.2	0.2	0.2	N	O
8.2	CD	8.2	8.2	8.2	N	O
0.4	CD	0.4	0.4	0.4	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
And	CC	and	and	and	N	O
Connective	NNP	connective	connective	connect	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Back	RB	back	back	back	N	B-AdverseReaction
Pain	NNP	pain	pain	pain	Y	I-AdverseReaction
28.6	CD	28.6	28.6	28.6	N	O
2.5	CD	2.5	2.5	2.5	N	O
22.4	CD	22.4	22.4	22.4	N	O
3.0	CD	3.0	3.0	3.0	N	O

Arthralgia	NNP	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
21.4	CD	21.4	21.4	21.4	N	O
1.6	CD	1.6	1.6	1.6	N	O
16.1	CD	16.1	16.1	16.1	N	O
1.1	CD	1.1	1.1	1.1	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
23.2	CD	23.2	23.2	23.2	N	O
0.7	CD	0.7	0.7	0.7	N	O
17.3	CD	17.3	17.3	17.3	N	O
0.4	CD	0.4	0.4	0.4	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
16.8	CD	16.8	16.8	16.8	N	O
0.3	CD	0.3	0.3	0.3	N	O
14.3	CD	14.3	14.3	14.3	N	O
0.4	CD	0.4	0.4	0.4	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Hot	NNP	hot	hot	hot	N	B-AdverseReaction
Flush	NNP	flush	flush	flush	N	I-AdverseReaction
18.0	CD	18.0	18.0	18.0	N	O
0.1	CD	0.1	0.1	0.1	N	O
7.8	CD	7.8	7.8	7.8	N	O
0.0	CD	0.0	0.0	0.0	N	O

Hypertension	NNP	hypertension	hypertension	hypertens	Y	B-AdverseReaction
14.2	CD	14.2	14.2	14.2	N	O
7.2	CD	7.2	7.2	7.2	N	O
4.1	CD	4.1	4.1	4.1	N	O
2.3	CD	2.3	2.3	2.3	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
System	NNP	system	system	system	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Dizzinessc	NNP	dizzinessc	dizzinessc	dizzinessc	N	B-AdverseReaction
11.3	CD	11.3	11.3	11.3	N	O
0.3	CD	0.3	0.3	0.3	N	O
7.1	CD	7.1	7.1	7.1	N	O
0.0	CD	0.0	0.0	0.0	N	O

Headache	NNP	headache	headache	headach	Y	B-AdverseReaction
11.0	CD	11.0	11.0	11.0	N	O
0.2	CD	0.2	0.2	0.2	N	O
7.0	CD	7.0	7.0	7.0	N	O
0.4	CD	0.4	0.4	0.4	N	O

Dysgeusia	NNP	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
7.6	CD	7.6	7.6	7.6	N	O
0.1	CD	0.1	0.1	0.1	N	O
3.7	CD	3.7	3.7	3.7	N	O
0.0	CD	0.0	0.0	0.0	N	O

Mental	JJ	mental	mental	mental	N	B-AdverseReaction
Impairment	NNP	impairment	impairment	impair	N	I-AdverseReaction
Disordersd	NNP	disordersd	disordersd	disordersd	N	I-AdverseReaction
5.7	CD	5.7	5.7	5.7	N	O
0.0	CD	0.0	0.0	0.0	N	O
1.3	CD	1.3	1.3	1.3	N	O
0.1	CD	0.1	0.1	0.1	N	O

Restless	NNP	restless	restless	restless	Y	B-AdverseReaction
Legs	NNP	legs	leg	leg	N	I-AdverseReaction
Syndrome	NNP	syndrome	syndrome	syndrom	N	I-AdverseReaction
2.1	CD	2.1	2.1	2.1	N	O
0.1	CD	0.1	0.1	0.1	N	O
0.4	CD	0.4	0.4	0.4	N	O
0.0	CD	0.0	0.0	0.0	N	O

Respiratory	NN	respiratory	respiratory	respiratori	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Dyspneae	NNP	dyspneae	dyspneae	dyspnea	N	B-AdverseReaction
11.0	CD	11.0	11.0	11.0	N	O
0.6	CD	0.6	0.6	0.6	N	O
8.5	CD	8.5	8.5	8.5	N	O
0.6	CD	0.6	0.6	0.6	N	O

Infections	NNS	infections	infection	infect	N	O
And	CC	and	and	and	N	O
Infestations	NNS	infestations	infestation	infest	N	O

Upper	NNP	upper	upper	upper	N	B-AdverseReaction
Respiratory	NNP	respiratory	respiratory	respiratori	N	I-AdverseReaction
Tract	NNP	tract	tract	tract	N	I-AdverseReaction
Infectionf	NNP	infectionf	infectionf	infectionf	N	I-AdverseReaction
16.4	CD	16.4	16.4	16.4	N	O
0.0	CD	0.0	0.0	0.0	N	O
10.5	CD	10.5	10.5	10.5	N	O
0.0	CD	0.0	0.0	0.0	N	O

Lower	JJR	lower	lower	lower	N	B-AdverseReaction
Respiratory	NNP	respiratory	respiratory	respiratori	N	I-AdverseReaction
Tract	NNP	tract	tract	tract	N	I-AdverseReaction
And	CC	and	and	and	N	O
Lung	NNP	lung	lung	lung	N	B-AdverseReaction
Infectiong	NNP	infectiong	infectiong	infectiong	N	I-AdverseReaction
7.9	CD	7.9	7.9	7.9	N	O
1.5	CD	1.5	1.5	1.5	N	O
4.7	CD	4.7	4.7	4.7	N	O
1.1	CD	1.1	1.1	1.1	N	O

Psychiatric	JJ	psychiatric	psychiatric	psychiatr	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Insomnia	NNP	insomnia	insomnia	insomnia	Y	B-AdverseReaction
8.2	CD	8.2	8.2	8.2	N	O
0.1	CD	0.1	0.1	0.1	N	O
5.7	CD	5.7	5.7	5.7	N	O
0.0	CD	0.0	0.0	0.0	N	O

Renal	NNP	renal	renal	renal	N	O
And	CC	and	and	and	N	O
Urinary	NNP	urinary	urinary	urinari	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Hematuria	NNP	hematuria	hematuria	hematuria	Y	B-AdverseReaction
8.8	CD	8.8	8.8	8.8	N	O
1.3	CD	1.3	1.3	1.3	N	O
5.8	CD	5.8	5.8	5.8	N	O
1.3	CD	1.3	1.3	1.3	N	O

Injury	NNP	injury	injury	injuri	Y	O
,	,	,	,	,	N	O
Poisoning	NNP	poisoning	poisoning	poison	Y	O
And	CC	and	and	and	N	O
Procedural	NNP	procedural	procedural	procedur	N	O
Complications	NNP	complications	complication	complic	N	O

Fall	NN	fall	fall	fall	Y	B-AdverseReaction
12.7	CD	12.7	12.7	12.7	N	O
1.6	CD	1.6	1.6	1.6	N	O
5.3	CD	5.3	5.3	5.3	N	O
0.7	CD	0.7	0.7	0.7	N	O

Non	NNP	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Pathological	JJ	pathological	pathological	patholog	N	I-AdverseReaction
Fracture	NN	fracture	fracture	fractur	Y	I-AdverseReaction
8.8	CD	8.8	8.8	8.8	N	O
2.1	CD	2.1	2.1	2.1	N	O
3.0	CD	3.0	3.0	3.0	N	O
1.1	CD	1.1	1.1	1.1	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
Nutrition	NN	nutrition	nutrition	nutrit	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Decreased	VBN	decreased	decreased	decreas	N	B-AdverseReaction
Appetite	NNP	appetite	appetite	appetit	N	I-AdverseReaction
18.9	CD	18.9	18.9	18.9	N	O
0.3	CD	0.3	0.3	0.3	N	O
16.4	CD	16.4	16.4	16.4	N	O
0.7	CD	0.7	0.7	0.7	N	O

Investigations	NNS	investigations	investigation	investig	N	O

Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
12.4	CD	12.4	12.4	12.4	N	O
0.8	CD	0.8	0.8	0.8	N	O
8.5	CD	8.5	8.5	8.5	N	O
0.2	CD	0.2	0.2	0.2	N	O

Reproductive	JJ	reproductive	reproductive	reproduct	N	O
System	NNP	system	system	system	N	O
and	CC	and	and	and	N	O
Breast	NNP	breast	breast	breast	N	O
disorders	NNS	disorders	disorder	disord	N	O

Gynecomastia	NNP	gynecomastia	gynecomastia	gynecomastia	Y	B-AdverseReaction
3.4	CD	3.4	3.4	3.4	N	O
0.0	CD	0.0	0.0	0.0	N	O
1.4	CD	1.4	1.4	1.4	N	O
0.0	CD	0.0	0.0	0.0	N	O

a	DT	a	a	a	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
v4b	NN	v4b	v4b	v4b	N	O
Includes	NNP	includes	includes	includ	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
.	.	.	.	.	N	O
c	VB	c	c	c	N	O
Includes	NNP	includes	includes	includ	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
and	CC	and	and	and	N	O
vertigo	NN	vertigo	vertigo	vertigo	Y	B-AdverseReaction
.	.	.	.	.	N	O
d	NN	d	d	d	N	O
Includes	NNP	includes	includes	includ	N	O
amnesia	NN	amnesia	amnesia	amnesia	Y	B-AdverseReaction
,	,	,	,	,	N	O
memory	NN	memory	memory	memori	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
,	,	,	,	,	N	O
cognitive	JJ	cognitive	cognitive	cognit	N	B-AdverseReaction
disorder	NN	disorder	disorder	disord	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
disturbance	NN	disturbance	disturbance	disturb	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
attention	NN	attention	attention	attent	N	I-AdverseReaction
.	.	.	.	.	N	O
e	NN	e	e	e	N	O
Includes	NNP	includes	includes	includ	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
exertional	JJ	exertional	exertional	exert	N	B-AdverseReaction
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
at	IN	at	at	at	N	I-AdverseReaction
rest	NN	rest	rest	rest	N	I-AdverseReaction
.	.	.	.	.	N	O
f	VB	f	f	f	N	O
Includes	NNP	includes	includes	includ	N	O
nasopharyngitis	NN	nasopharyngitis	nasopharyngitis	nasopharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
upper	JJ	upper	upper	upper	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
sinusitis	NN	sinusitis	sinusitis	sinus	Y	B-AdverseReaction
,	,	,	,	,	N	O
rhinitis	NN	rhinitis	rhinitis	rhiniti	Y	B-AdverseReaction
,	,	,	,	,	N	O
pharyngitis	NN	pharyngitis	pharyngitis	pharyng	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
laryngitis	NN	laryngitis	laryngitis	laryng	Y	B-AdverseReaction
.	.	.	.	.	N	O
g	NN	g	g	g	N	O
Includes	NNP	includes	includes	includ	N	O
pneumonia	NN	pneumonia	pneumonia	pneumonia	Y	B-AdverseReaction
,	,	,	,	,	N	O
lower	JJR	lower	lower	lower	N	B-AdverseReaction
respiratory	NN	respiratory	respiratory	respiratori	N	I-AdverseReaction
tract	JJ	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
,	,	,	,	,	N	O
bronchitis	NN	bronchitis	bronchitis	bronchiti	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
lung	NN	lung	lung	lung	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
.	.	.	.	.	N	O

Laboratory	NN	laboratory	laboratory	laboratori	N	O
Abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
randomized	VBD	randomized	randomized	random	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
1	CD	1	1	1	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
15%	CD	15%	15%	15%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
6%	CD	6%	6%	6%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Grade	NNP	grade	grade	grade	N	B-Severity
1	CD	1	1	1	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
6%	CD	6%	6%	6%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
(	(	(	(	(	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
0.5%	CD	0.5%	0.5%	0.5%	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Grade	$	grade	grade	grade	N	B-Severity
1	CD	1	1	1	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
10%	CD	10%	10%	10%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
(	(	(	(	(	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
16%	CD	16%	16%	16%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
0.2%	CD	0.2%	0.2%	0.2%	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Grade	$	grade	grade	grade	N	B-Severity
1	CD	1	1	1	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
elevations	NNS	elevations	elevation	elev	N	B-AdverseReaction
in	IN	in	in	in	N	I-AdverseReaction
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
3%	CD	3%	3%	3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
(	(	(	(	(	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
2%	CD	2%	2%	2%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
(	(	(	(	(	N	O
no	DT	no	no	no	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Infections	NNS	infections	infection	infect	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
0.3%	CD	0.3%	0.3%	0.3%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
died	VBN	died	died	die	N	B-AdverseReaction
from	IN	from	from	from	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
or	CC	or	or	or	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
patient	NN	patient	patient	patient	N	O
in	IN	in	in	in	N	O
each	DT	each	each	each	N	O
treatment	NN	treatment	treatment	treatment	N	O
group	NN	group	group	group	N	O
(	(	(	(	(	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
)	)	)	)	)	N	O
had	VBD	had	had	had	N	O
an	DT	an	an	an	N	O
infection	NN	infection	infection	infect	Y	B-AdverseReaction
resulting	VBG	resulting	resulting	result	N	O
in	IN	in	in	in	N	O
death	NN	death	death	death	Y	B-AdverseReaction
.	.	.	.	.	N	O

Falls	NNS	falls	fall	fall	N	O
and	CC	and	and	and	N	O
Fall	NNP	fall	fall	fall	Y	O
-	:	-	-	-	N	O
related	JJ	related	related	relat	N	O
Injuries	NNS	injuries	injury	injuri	N	O
In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
randomized	VBD	randomized	randomized	random	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
falls	VBZ	falls	fall	fall	N	B-AdverseReaction
including	VBG	including	including	includ	N	O
fall	VB	fall	fall	fall	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
injuries	NNS	injuries	injury	injuri	N	I-AdverseReaction
,	,	,	,	,	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
9%	CD	9%	9%	9%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

Falls	NNS	falls	fall	fall	N	B-AdverseReaction
were	VBD	were	were	were	N	O
not	RB	not	not	not	N	B-Negation
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
loss	NN	loss	loss	loss	N	B-AdverseReaction
of	IN	of	of	of	N	I-AdverseReaction
consciousness	NN	consciousness	consciousness	conscious	N	I-AdverseReaction
or	CC	or	or	or	N	O
seizure	NN	seizure	seizure	seizur	Y	B-AdverseReaction
.	.	.	.	.	N	O

Fall	NNP	fall	fall	fall	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
injuries	NNS	injuries	injury	injuri	N	I-AdverseReaction
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
severe	JJ	severe	severe	sever	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
and	CC	and	and	and	N	O
included	VBD	included	included	includ	N	O
non	SYM	non	non	non	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
pathologic	NN	pathologic	pathologic	patholog	N	I-AdverseReaction
fractures	NNS	fractures	fracture	fractur	N	I-AdverseReaction
,	,	,	,	,	N	O
joint	JJ	joint	joint	joint	N	B-AdverseReaction
injuries	NNS	injuries	injury	injuri	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
hematomas	NN	hematomas	hematoma	hematoma	N	B-AdverseReaction
.	.	.	.	.	N	O

Hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
two	CD	two	two	two	N	O
randomized	JJ	randomized	randomized	random	N	O
trials	NNS	trials	trial	trial	N	O
,	,	,	,	,	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
11%	CD	11%	11%	11%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
and	CC	and	and	and	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
placebo	NN	placebo	placebo	placebo	N	O
.	.	.	.	.	N	O

No	DT	no	no	no	N	B-Negation
patients	NNS	patients	patient	patient	N	O
experienced	VBD	experienced	experienced	experienc	N	O
hypertensive	JJ	hypertensive	hypertensive	hypertens	Y	B-AdverseReaction
crisis	NN	crisis	crisis	crisi	N	I-AdverseReaction
.	.	.	.	.	N	O

Medical	JJ	medical	medical	medic	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
hypertension	NN	hypertension	hypertension	hypertens	Y	O
was	VBD	was	wa	wa	N	O
balanced	VBN	balanced	balanced	balanc	N	O
between	IN	between	between	between	N	O
arms	NNS	arms	arm	arm	N	O
.	.	.	.	.	N	O

Hypertension	NN	hypertension	hypertension	hypertens	Y	B-AdverseReaction
led	VBD	led	led	led	N	O
to	TO	to	to	to	N	O
study	VB	study	study	studi	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
1%	CD	1%	1%	1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
in	IN	in	in	in	N	O
each	DT	each	each	each	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Seizure	NN	seizure	seizure	seizur	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
XTANDI	NN	xtandi	xtandi	xtandi	N	O
who	WP	who	who	who	N	O
previously	RB	previously	previously	previous	N	O
received	VBD	received	received	receiv	N	O
docetaxel	NN	docetaxel	docetaxel	docetaxel	N	O
and	CC	and	and	and	N	O
in	IN	in	in	in	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
were	VBD	were	were	were	N	O
chemotherapy	JJ	chemotherapy	chemotherapy	chemotherapi	Y	O
-	:	-	-	-	N	O
naive	NN	naive	naive	naiv	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
no	DT	no	no	no	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
experience	NN	experience	experience	experi	N	O
with	IN	with	with	with	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
had	VBD	had	had	had	N	O
a	DT	a	a	a	N	O
seizure	NN	seizure	seizure	seizur	Y	O
.	.	.	.	.	N	O

Permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
a	DT	a	a	a	N	O
seizure	NN	seizure	seizure	seizur	Y	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Seizure	NN	seizure	seizure	seizur	Y	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
which	WDT	which	which	which	N	O
enrolled	VBD	enrolled	enrolled	enrol	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
previously	RB	previously	previously	previous	N	O
received	VBD	received	received	receiv	N	O
docetaxel	NN	docetaxel	docetaxel	docetaxel	N	O
,	,	,	,	,	N	O
7	CD	7	7	7	N	O
of	IN	of	of	of	N	O
800	CD	800	800	800	N	O
(	(	(	(	(	N	O
0.9%	CD	0.9%	0.9%	0.9%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
experienced	VBD	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
seizure	NN	seizure	seizure	seizur	Y	B-AdverseReaction
and	CC	and	and	and	N	O
no	DT	no	no	no	N	B-Negation
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
experienced	VBD	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
seizure	NN	seizure	seizure	seizur	Y	B-AdverseReaction
.	.	.	.	.	N	O

Seizure	NN	seizure	seizure	seizur	Y	B-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
from	IN	from	from	from	N	O
31	CD	31	31	31	N	O
to	TO	to	to	to	N	O
603	CD	603	603	603	N	O
days	NNS	days	day	day	N	O
after	IN	after	after	after	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
,	,	,	,	,	N	O
1	CD	1	1	1	N	O
of	IN	of	of	of	N	O
871	CD	871	871	871	N	O
(	(	(	(	(	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
)	)	)	)	)	N	O
chemotherapy	NN	chemotherapy	chemotherapy	chemotherapi	Y	O
-	:	-	-	-	N	O
naive	JJ	naive	naive	naiv	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
and	CC	and	and	and	N	O
1	CD	1	1	1	N	O
of	IN	of	of	of	N	O
844	CD	844	844	844	N	O
(	(	(	(	(	N	O
0.1%	CD	0.1%	0.1%	0.1%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
placebo	NN	placebo	placebo	placebo	N	O
experienced	VBD	experienced	experienced	experienc	N	O
a	DT	a	a	a	N	O
seizure	NN	seizure	seizure	seizur	Y	B-AdverseReaction
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
seizure	NN	seizure	seizure	seizur	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
permanently	RB	permanently	permanently	perman	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
from	IN	from	from	from	N	O
therapy	NN	therapy	therapy	therapi	N	O
and	CC	and	and	and	N	O
all	DT	all	all	all	N	O
seizure	NN	seizure	seizure	seizur	Y	O
events	NNS	events	event	event	N	O
resolved	VBD	resolved	resolved	resolv	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
is	VBZ	is	is	is	N	O
no	DT	no	no	no	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
experience	NN	experience	experience	experi	N	O
re	NN	re	re	re	N	O
-	:	-	-	-	N	O
administering	VBG	administering	administering	administ	N	O
XTANDI	NN	xtandi	xtandi	xtandi	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
experienced	VBD	experienced	experienced	experienc	N	O
seizure	NN	seizure	seizure	seizur	Y	O
.	.	.	.	.	N	O

Limited	JJ	limited	limited	limit	N	O
safety	NN	safety	safety	safeti	N	O
data	NNS	data	data	data	N	O
are	VBP	are	are	are	N	O
available	JJ	available	available	avail	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
predisposing	JJ	predisposing	predisposing	predispos	N	O
factors	NNS	factors	factor	factor	N	O
for	IN	for	for	for	N	O
seizure	NN	seizure	seizure	seizur	Y	O
because	IN	because	because	becaus	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
generally	RB	generally	generally	gener	N	O
excluded	VBN	excluded	excluded	exclud	N	O
from	IN	from	from	from	N	O
the	DT	the	the	the	N	O
trials	NNS	trials	trial	trial	N	O
.	.	.	.	.	N	O

These	DT	these	these	these	N	O
exclusion	NN	exclusion	exclusion	exclus	N	O
criteria	NNS	criteria	criterion	criteria	N	O
included	VBD	included	included	includ	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
seizure	NN	seizure	seizure	seizur	Y	O
,	,	,	,	,	N	O
underlying	VBG	underlying	underlying	underli	N	O
brain	NN	brain	brain	brain	N	O
injury	NN	injury	injury	injuri	Y	O
with	IN	with	with	with	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
consciousness	NN	consciousness	consciousness	conscious	N	O
,	,	,	,	,	N	O
transient	JJ	transient	transient	transient	N	O
ischemic	JJ	ischemic	ischemic	ischem	N	O
attack	NN	attack	attack	attack	N	O
within	IN	within	within	within	N	O
the	DT	the	the	the	N	O
past	JJ	past	past	past	N	O
12	CD	12	12	12	N	O
months	NNS	months	month	month	N	O
,	,	,	,	,	N	O
cerebral	JJ	cerebral	cerebral	cerebr	N	O
vascular	JJ	vascular	vascular	vascular	N	O
accident	NN	accident	accident	accid	Y	O
,	,	,	,	,	N	O
brain	NN	brain	brain	brain	N	O
metastases	NNS	metastases	metastasis	metastas	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
brain	NN	brain	brain	brain	N	O
arteriovenous	JJ	arteriovenous	arteriovenous	arterioven	N	O
malformation	NN	malformation	malformation	malform	N	O
.	.	.	.	.	N	O

Study	NNP	study	study	studi	N	O
1	CD	1	1	1	N	O
excluded	VBD	excluded	excluded	exclud	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
medications	NNS	medications	medication	medic	N	O
that	WDT	that	that	that	N	O
may	MD	may	may	may	N	O
lower	VB	lower	lower	lower	N	O
the	DT	the	the	the	N	O
seizure	NN	seizure	seizure	seizur	Y	O
threshold	NN	threshold	threshold	threshold	N	O
,	,	,	,	,	N	O
whereas	WP	whereas	whereas	wherea	N	O
Study	NNP	study	study	studi	N	O
2	CD	2	2	2	N	O
permitted	VBD	permitted	permitted	permit	N	O
the	DT	the	the	the	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
these	DT	these	these	these	N	O
medications	NNS	medications	medication	medic	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
seizure	NN	seizure	seizure	seizur	Y	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
use	NN	use	use	use	N	O
,	,	,	,	,	N	O
patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
advised	VBN	advised	advised	advis	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
risk	NN	risk	risk	risk	N	O
of	IN	of	of	of	N	O
engaging	VBG	engaging	engaging	engag	N	O
in	IN	in	in	in	N	O
any	DT	any	any	ani	N	O
activity	NN	activity	activity	activ	N	O
where	WRB	where	where	where	N	O
sudden	JJ	sudden	sudden	sudden	N	O
loss	NN	loss	loss	loss	N	O
of	IN	of	of	of	N	O
consciousness	NN	consciousness	consciousness	conscious	N	O
could	MD	could	could	could	N	O
cause	VB	cause	cause	caus	N	O
serious	JJ	serious	serious	seriou	N	O
harm	NN	harm	harm	harm	N	O
to	TO	to	to	to	N	O
themselves	PRP	themselves	themselves	themselv	N	O
or	CC	or	or	or	N	O
others	NNS	others	others	other	N	O
.	.	.	.	.	N	O

Permanently	RB	permanently	permanently	perman	N	O
discontinue	JJ	discontinue	discontinue	discontinu	N	O
XTANDI	NNP	xtandi	xtandi	xtandi	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
develop	VBP	develop	develop	develop	N	O
a	DT	a	a	a	N	O
seizure	NN	seizure	seizure	seizur	Y	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
.	.	.	.	.	N	O

